<DOC>
	<DOCNO>NCT01208948</DOCNO>
	<brief_summary>To evaluate effect alpha lipoic acid ( ALA ) occurrence diabetic macular edema .</brief_summary>
	<brief_title>Clinical Trial Alpha Lipoic Acid Diabetic Macular Edema</brief_title>
	<detailed_description>Randomised , double-blind , placebo control multicentre study . Patients randomise treatment group 600 mg ALA per day placebo group . At examination take stereo fundus photograph , HbA1c level , perform ophthalmological examination . Primary endpoint study occurrence clinically significant macular edema ( CSME ) within follow-up period 2 year .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>Diabetes type II , mild non proliferative diabetic retinopathy , Microalbuminuria &gt; 30 mg/L Ophthalmic exclusion criterion severe nonproliferative proliferative diabetic retinopathy Macular edema Eye diseases interfere examination fundus preretinal haemorrhage , cataract , vitreous haemorrhage Amblyopia Best correct visual acuity ( VA ) 0.5 Glaucoma Patients cataract surgery within period three month Other relevant retinal disease Nonauthorized interventional therapy diabetic retinopathy ( e.g . laser , kryocoagulation , vitrectomy ) General exclusion criterion Chronic administration alpha lipoic acid five successive day last twelve month Known intolerance/hypersensitivity alpha lipoic acid Type I diabetes mellitus Poor metabolic control HbA1c &gt; 10.5 % /dl Late sequela diabetes organic manifestation ( e.g . dialysis case renal insufficiency , history kidney transplantation , creatinine &gt; 1.6 mg/dl ) Poorly control arterial hypertension ( systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 95 mmHg ) Severe disturbances lipid metabolism ( triglycerides &gt; 500 mg/dl total cholesterol &gt; 320 mg/dl ) Unpermitted concomitant medication define medicine potential interaction alpha lipoic acid effect alpha lipoic acid exclude concomitant medication . These include aldose reductase inhibitor , substance promote blood flow , anticoagulant apart acetylsalicylic acid 500 mg/day shortterm treatment disease normal dose acetylsalicylic acid , chronically systemically administer corticosteroid , hormonal contraceptive Malignancies life threaten disease Drug alcohol abuse Blood donation blood loss great 500 ml ) within last 3 month Pregnancy breast feeding Participation clinical trial within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>macular edema</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>prevention alpha lipoic acid</keyword>
</DOC>